PLARIUM
2.4.2020 15:02:07 CEST | Business Wire | Press release
Plarium, a leading developer of mobile, social, and web-based games with more than 290 million players worldwide, is proud to announce the launch of its latest genre-defining casual adventure title, Undersea Solitaire Tripeaks , on Android and iOS. This story-driven game offers the excitement of Solitaire Tripeaks immersed in an engrossing narrative blended with item collection and town-designing features.
The game takes place in the typically idyllic undersea town of Rocky Bottom which has been blown to pieces by a nasty whirlpool. Players must earn gems through their sweet solitaire skills to help Alfred the Crab and his fishy friends rebuild the town and make it bigger than ever before! Along the journey, players will uncover ancient artifacts, host fashion shows, welcome new residents, solve crimes, and much more.
“Plarium has been developing narrative-driven games in the strategy and RPG genres for many years, and we see a strong demand from our casual audiences for the same type of experience,” says Oleg Yakovlev, game producer at Plarium. “This is why we focused on building the first game to blend Solitaire mechanics, a narrative-driven metagame, and town customization gameplay to give players a new challenge unlike anything they have seen before in this genre!”
Undersea Solitaire Tripeaks features 30+ animated 3D characters and over 2000 intricately designed levels with a variety of gameplay mechanics to keep players engaged and entertained. Key gameplay elements include:
- The most ‘blockers’ and ‘boosters’ of any solitaire game: Undersea Solitaire Tripeaks has 15+ unique blockers and 6 boosters to offer players endless challenges.
- 600+ exciting story quests: Players will work alongside a diverse cast of characters to help grow Rocky Bottom into a bustling place with a circus, amphitheater, theme park, and more.
- Epic Challenges Every Day of the Week: Undersea Solitaire Tripeaks features a host of special Solitaire events, daily missions, and much more.
- Thousands of town customization options: Players can rebuild Rocky Bottom just the way they want.
Undersea Solitaire Tripeaks is now available for users worldwide in English, French, German, Italian, Japanese, Korean, Russian, Spanish, Turkish, Traditional Chinese, Simplified Chinese, and Portuguese. It can be accessed through the App Store and Google Play .
About Plarium
Founded in 2009, Plarium Global Ltd. is dedicated to creating the best mobile and social experience for hardcore and casual gamers worldwide. With over 290 million registered users, we're proud to be consistently ranked among Facebook’s top hardcore game developers. Plarium employs more than 1400 individuals and is headquartered in Israel with eight offices and development studios across Europe and the United States. Our games are available on iOS, Android, and Plarium Play, as well as all major social networks, including Facebook, VKontakte, Odnoklassniki and Mail.ru and web browsers. Plarium was acquired by Aristocrat in October 2017 and operates as a wholly owned subsidiary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom